pulmonary arterial hypertension

May 19, 2015November 5, 2015

Bayer Presents New Research on Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension at 2015 ATS Annual Conference

During the 2015 Annual International Conference of the American Thoracic Society (ATS), Bayer HealthCare is presenting recent research on chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). The conference is taking ... Read more

May 15, 2015November 5, 2015

Actelion’s Encouraging Clinical Trial Results on PAH Therapies to be Presented at Upcoming Scientific Meeting

News, Pulmonary Hypertension

Actelion Pharmaceuticals Ltd recently announced in a press release that data from its Phase III trials on the drugs selexipag (Uptravi) and macitentan (Opsumit) will be presented at the upcoming ... Read more

April 20, 2015November 5, 2015

Salidroside Herb Found To Reduce Chronic Hypoxia-induced Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

According to a recent study published in the Journal of Molecular and Cellular Cardiology, an herb called Salidroside can reduce chronic hypoxia-induced Pulmonary arterial hypertension by promoting PASMCs apoptosis via an A2aR related ... Read more

April 15, 2015November 5, 2015

FDA Grants Reata Pharmaceuticals’ Bardoxolone Methyl Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Reata Pharmaceuticals, Inc., an Irving, Texas-based biopharmaceutical company developing transcription-regulating activity drugs called antioxidant inflammation modulators (AIMs), recently announced that the Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) ... Read more

April 7, 2015November 5, 2015

Actavis Files ANDA for Generic Ambrisentan Tablets for PAH

News, Pulmonary Hypertension

Actavis recently confirmed that the company has filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA) seeking approval to commercialize their formulation of Ambrisentan Tablets (5 and 10 mg). ... Read more

March 31, 2015November 5, 2015

Opsumit Granted Marketing Approval in Japan for PAH

News, Pulmonary Hypertension

The Japanese Ministry of Health Labor and Welfare has granted marketing approval for a novel therapy developed by Actelion for pulmonary arterial hypertension (PAH). Opsumit (macitentan) was approved based on the latest data ... Read more

March 27, 2015November 5, 2015

Serial Risk Score For Pulmonary Arterial Hypertension Helps Predict Disease Outcomes

News, Pulmonary Hypertension

In a recent study entitled “Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management ... Read more

March 23, 2015November 5, 2015

Long-term Data on Selexipag for PAH Presented at American College of Cardiology (ACC) 2015

News, Pulmonary Hypertension

Actelion Ltd recently presented long-term results at the American College of Cardiology (ACC) Congress in San Diego, US from their pivotal selexipag (Uptravi®) Phase III GRIPHON trial. The company reported that, ... Read more

March 10, 2015November 5, 2015

Researchers Review Importance of Non-Invasive Imaging in Diagnosis and Management of PAH

News, Pulmonary Hypertension

A recently accepted manuscript on the Canadian Journal of Cardiology, an open access journal, provides an overview of the current clinical use of noninvasive imagining techniques, such as echocardiography, for pulmonary ... Read more

March 9, 2015November 5, 2015

Results of SERAPHIN Trial Show Macitentan PAH Treatment Decreases Hospitalization Risk

News, Pulmonary Hypertension

A group of international pulmonary medical specialists have conducted a clinical trial to assess improvement in hospital based outcomes in patients with pulmonary arterial hypertension (PAH) when treated with macitentan, ... Read more